Ko-Chung Lin, founder and CEO of PharmaEssentia, documents the main specificities of the company’s groundbreaking ropeginterferon alfa-2b, a once-every-two-week interferon displaying a unique toxicity profile. In this regard, Mr. Lin also provides insights into PharmaEssentia’s approach to the upcoming launch of this product into the US market as well as his vision for the international development of the company, which already stands as one of the most advanced and ambitious biopharmaceutical companies headquartered in Taiwan. On December 5th 2016, PharmaEssentia announced eye-catching phase III results for its Ropeginterferon Alfa-2b in Polycythemia Vera (PV) at the American Society of Hematology (ASH)’s Annual Meeting 2016. Why do these results stand as great news for patients?
"PharmaEssentia is on the verge of bringing what we believe is a significant, safe, and efficacious new therapy to patients with Polycythemia Vera (PV)."